

Andrea Nicolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4875004/publications.pdf>

Version: 2024-02-01

79
papers

2,178
citations

236612

25
h-index

233125

45
g-index

81
all docs

81
docs citations

81
times ranked

3274
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline genetic variability in pancreatic cancer risk and prognosis. <i>Seminars in Cancer Biology</i> , 2022, 79, 105-131.	4.3	30
2	Tumor reversion and embryo morphogenetic factors. <i>Seminars in Cancer Biology</i> , 2022, 79, 83-90.	4.3	16
3	Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity. <i>Seminars in Cancer Biology</i> , 2022, 79, 68-82.	4.3	15
4	Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1665.	1.8	48
5	A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. <i>Cancers</i> , 2022, 14, 2527.	1.7	8
6	Exosomes and Cell Communication: From Tumour-Derived Exosomes and Their Role in Tumour Progression to the Use of Exosomal Cargo for Cancer Treatment. <i>Cancers</i> , 2021, 13, 822.	1.7	40
7	New biological and immunological approaches to cancer therapy: Basic and clinical aspects. <i>Seminars in Cancer Biology</i> , 2021, 79, 1-1.	4.3	0
8	A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. <i>Journal of Molecular Medicine</i> , 2020, 98, 375-382.	1.7	7
9	Limiting research on molecular targeted therapies in advanced solid cancers: beyond a cost-effectiveness ratio analysis. <i>Biomarkers in Medicine</i> , 2019, 13, 887-890.	0.6	1
10	The Use of Immunotherapy to Treat Metastatic Breast Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 941-962.	1.2	14
11	Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5986.	1.8	6
12	Overcoming Endocrine Resistance in Breast Cancer. , 2019, , 393-422.		2
13	Quercetin conjugated with silica nanoparticles inhibits tumor growth in MCF-7 breast cancer cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 860-865.	1.0	61
14	Prognostic and predictive biomarkers in breast cancer: Past, present and future. <i>Seminars in Cancer Biology</i> , 2018, 52, 56-73.	4.3	284
15	An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6879-6886.	0.9	6
16	Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2733.	1.8	9
17	Tumour growth and immune evasion as targets for a new strategy in advanced cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R577-R604.	1.6	27
18	The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy. <i>Current Drug Targets</i> , 2018, 20, 81-86.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Biomarkers and the "target therapies"™ in oncology, research and business. <i>Biomarkers in Medicine</i> , 2017, 11, 217-219.	0.6	1
20	Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2321.	1.8	8
21	Editorial (Thematic Issue: The Biological Approach to Advanced Cancer: Are We in the Middle of the) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	1.0	0
22	Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy. <i>Current Drug Targets</i> , 2016, 17, 1103-1110.	1.0	34
23	Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update. <i>Current Drug Targets</i> , 2016, 17, 1127-1139.	1.0	37
24	Biomarkers: a framework driving advances in oncology. <i>Biomarkers in Medicine</i> , 2015, 9, 303-306.	0.6	2
25	An individual reference limit for "early"™ diagnosis of metastatic breast cancer during postoperative follow-up. <i>Biomarkers in Medicine</i> , 2015, 9, 307-317.	0.6	7
26	Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 197-225.	0.8	13
27	The PI3K-Akt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 804-815.	0.9	22
28	Cellular Plasticity, Cancer Stem Cells and Metastasis. , 2015, , 13-66.		0
29	Editorial (Thematic Issue: Endocrine Related Cancer: From Stem Cells to New Drug Targets). <i>Current Medicinal Chemistry</i> , 2014, 21, 1071-1071.	1.2	0
30	Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease. <i>Pathology and Oncology Research</i> , 2014, 20, 267-276.	0.9	19
31	Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 171-178.	2.5	10
32	Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 807-817.	2.5	127
33	Targeted therapies of metastatic breast cancer: Relationships with cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 543-555.	2.5	11
34	Defective Generation and Maturation of Dendritic Cells from Monocytes in Colorectal Cancer Patients during the Course of Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 22022-22041.	1.8	41
35	Does Large Needle Aspiration Biopsy Add Pain to the Thyroid Nodule Evaluation?. <i>PLoS ONE</i> , 2013, 8, e58016.	1.1	12
36	Breast cancer stem cells: new therapeutic approaches. <i>Breast Cancer Management</i> , 2012, 1, 277-294.	0.2	1

#	ARTICLE	IF	CITATIONS
37	An iron regulatory gene signature in breast cancer: more than a prognostic genetic profile?. <i>Future Oncology</i> , 2012, 8, 131-134.	1.1	3
38	Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 414-418.	2.5	41
39	Are Risk Factors Common to Thyroid Cancer and Nodule? A Forty Years Observational Time-Trend Study. <i>PLoS ONE</i> , 2012, 7, e47758.	1.1	6
40	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
41	Additional 5-FU-LV significantly increases survival in gastrointestinal cancer. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1475-1482.	0.9	1
42	Large needle aspiration biopsy histology for preoperative selection of H ¹⁴ rthle cell thyroid nodules. <i>Histopathology</i> , 2011, 59, 892-896.	1.6	3
43	Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. <i>International Journal of Cancer</i> , 2011, 128, 3-11.	2.3	83
44	Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1859-1863.	1.8	59
45	A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect. <i>Tumor Biology</i> , 2010, 31, 523-532.	0.8	6
46	Thyroid tumor marker genomics and proteomics: Diagnostic and clinical implications. <i>Journal of Cellular Physiology</i> , 2010, 224, 612-619.	2.0	35
47	Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: A prospective cohort study. <i>Annals of Medicine</i> , 2010, 42, 70-78.	1.5	22
48	Intensive Risk-Adjusted Follow-up With the CEA, TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences. <i>Archives of Surgery</i> , 2010, 145, 1177.	2.3	40
49	Additional 5-FU-LV significantly increases survival in gastrointestinal cancer. <i>Frontiers in Bioscience - Elite</i> , 2009, E3, 1475.	0.9	0
50	Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology. <i>Medicinal Research Reviews</i> , 2009, 29, 436-471.	5.0	32
51	CXCL10 and CCL2 Chemokine Serum Levels in Patients With Hepatitis C Associated With Autoimmune Thyroiditis. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 345-352.	0.5	12
52	Î±-Chemokine CXCL10 and Î²-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1270-1277.	1.5	44
53	Varicella fulminant hepatitis in an adult patient with Factor V Leiden mutation and trisomy 8 related myelodysplastic syndrome. <i>Journal of Clinical Virology</i> , 2008, 43, 134-135.	1.6	0
54	Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epiphyseal trabecular bone of aged Dunkin Hartley guinea pigs. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 709-715.	2.5	66

#	ARTICLE	IF	CITATIONS
55	Molecular markers in breast cancer: no longer a "free" run from laboratory to the clinic. <i>Biomarkers in Medicine</i> , 2008, 2, 531-534.	0.6	0
56	Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPAR γ Agonists?. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2008, 2, 194-199.	0.7	0
57	Conventional and new emerging prognostic factors in breast cancer: an update. <i>Biomarkers in Medicine</i> , 2007, 1, 525-540.	0.6	4
58	Laparoscopic Cholecystectomy in an Adult with Complex-Corrected Congenital Heart Disease. <i>Anesthesia and Analgesia</i> , 2007, 104, 242-243.	1.1	3
59	Presence of a functional TSH receptor on human erythrocytes. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 463-467.	2.5	26
60	Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. <i>Cancer Letters</i> , 2007, 251, 330-338.	3.2	18
61	Large needle percutaneous aspiration biopsy of the testicle in men with nonobstructive azoospermia: technical performance. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 557-560.	2.5	5
62	Biomolecular markers of breast cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1818.	3.0	57
63	Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. <i>BMC Cancer</i> , 2006, 6, 269.	1.1	52
64	An Immunotherapy Schedule in Endocrine-Dependent Metastatic Breast Cancer. <i>Journal of Immunotherapy</i> , 2005, 28, 276-279.	1.2	26
65	Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, 253-263.	2.5	32
66	Serum tumor markers in the management of ovarian, endometrial and cervical cancer. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 24-38.	2.5	158
67	Large needle aspiration biopsy results of palpable thyroid nodules diagnosed by fine-needle aspiration as a microfollicular nodule with atypical cells or suspected cancer. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 351-355.	2.5	9
68	From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 356-359.	2.5	24
69	Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 451-457.	2.5	60
70	"Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 452-459.	2.5	33
71	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 232-235.	0.6	4
72	Utility of a Serum Tumour Marker Panel in the Post-Operative Follow-Up of Breast Cancer Patients with Equivocal Conventional Radiological Examinations. <i>Tumor Biology</i> , 2003, 24, 275-280.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Large-Needle Aspiration Biopsy for the Preoperative Selection of Follicular Adenoma Diagnosed by Fine-Needle Aspiration as a Microfollicular Nodule or Suspected Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 209-212.	0.6	17
74	Postoperative Follow-Up of Breast Cancer Patients: Overview and Progress in the Use of Tumor Markers. <i>Tumor Biology</i> , 2000, 21, 235-248.	0.8	36
75	Large-Needle Aspiration Biopsy for the Preoperative Selection of Palpable Thyroid Nodules Diagnosed by Fine-Needle Aspiration as a Microfollicular Nodule or Suspected Cancer. <i>American Journal of Clinical Pathology</i> , 2000, 113, 872-877.	0.4	24
76	Aspiration Needle Biopsy in Preoperative Selection of Thyroid Nodules Defined at Fine-Needle Aspiration as Microfollicular Lesions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 65-69.	0.6	14
77	Protocols for the Preoperative Selection of Palpable Thyroid Nodules. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 499.	0.6	15
78	A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. <i>Cancer</i> , 1989, 63, 2037-2046.	2.0	26
79	Serum thyroid hormone concentrations and recovery of TSH secretion after excision of autonomously functioning thyroid nodules. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 417-420.	1.5	2